Company news

Insmed Incorporated news in 2025

Insmed Incorporated's news releases, calls and decks from 2025, newest first.

View company

Insmed Provides Clinical and Business Update

December 16, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 3, 2025

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

November 17, 2025

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

November 12, 2025

Insmed To Present at November and December 2025 Investor Conferences

November 4, 2025

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

October 29, 2025

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

October 22, 2025

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

October 16, 2025

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

October 15, 2025

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

October 14, 2025

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

September 21, 2025

Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight

August 25, 2025

Insmed To Present at September Investor Conferences

August 20, 2025

VytlOne Announces New Partnership with Insmed

August 13, 2025

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

August 13, 2025

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

August 11, 2025

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

July 23, 2025

Insmed Announces Proposed $650 Million Public Offering of Common Stock

June 10, 2025

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

June 10, 2025

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

June 9, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

May 27, 2025

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

May 20, 2025

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

Insmed To Present at the BofA Securities 2025 Health Care Conference

April 28, 2025

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

April 23, 2025

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

April 22, 2025

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

April 22, 2025

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

March 24, 2025

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

February 23, 2025

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

February 19, 2025

Insmed To Present at March 2025 Investor Conferences

February 10, 2025

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

February 9, 2025

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

February 5, 2025

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Calls in 2025

Decks in 2025